Key result
H-Wave device stimulation reduces pain and medication use while improving function in musculoskeletal disorders.
Why the study?
The opioid crisis has driven a shift toward multimodal non-narcotic pain management, but electrotherapies remain understudied and largely lack high-quality clinical trials.
Does H-Wave device stimulation reduce pain, lower medication use, and improve functionality in patients with musculoskeletal and neuropathic pain?
Systematic Review (n=6,789)
Does H-Wave device stimulation reduce pain, lower medication use, and improve functionality in patients with musculoskeletal and neuropathic pain?
H-Wave device stimulation is a safe, non-opioid adjunctive therapy that may significantly reduce pain and medication use while improving functionality in patients with chronic pain conditions.
Answers are grounded in this paper and cite their sources.
May support H-Wave as non-opioid adjunct for neuropathic pain; leaves open confirmation in high-quality RCTs.
Pain treatments have historically centered on drugs, but an “opioid crisis” has necessitated new standards of care, with a paradigm shift towards multi-modal pain management emphasizing early movement, non-narcotics, and various adjunctive therapies. Electrotherapies remain understudied and most lack high-quality clinical trials, despite a desperate need for effective adjunctive options. A systematic search of human clinical studies on H-Wave® device stimulation (HWDS) was conducted as well as a comprehensive review of articles articulating possible HWDS mechanisms of action. Studies unrelated to H-Wave were excluded. Data synthesis summarizes outcomes and study designs, categorized as pre-clinical or clinical. Pre-clinical studies demonstrated that HWDS utilizes a biphasic waveform to induce non-fatiguing muscle contractions which positively affect nerve function, blood and lymph flow. Multiple clinical studies have reported significant benefits for diabetic and non-specific neuropathic pain, where function also improved, and pain medication usage substantially dropped. In conclusion, low- to moderate-quality HWDS studies have reported reduced pain, restored functionality, and lower medication use in a variety of disorders, although higher-quality research is needed to verify condition-specific applicability. HWDS has enough reasonable evidence to be considered as an adjunctive component of non-opioid multi-modal pain management, given its excellent safety profile and relative low cost. Level of Evidence: III.
No takes yet. Share an insight, caveat, or question.
Williamson et al. (2021) conducted a systematic review in Musculoskeletal and neuropathic pain (n=6,789). H-Wave device stimulation vs. Standard-of-care treatments or sham was evaluated on Global evaluation of subjectively decreased pain, reduced medication use and improved functionality. Low- to moderate-quality studies indicate that H-Wave device stimulation reduces pain, restores functionality, and lowers pain medication use in patients with neuropathic and musculoskeletal disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: